{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:12:57Z","timestamp":1707523977021},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,31]]},"DOI":"10.7759\/cureus.44433","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T11:25:34Z","timestamp":1693481134000},"source":"Crossref","is-referenced-by-count":0,"title":["Explosive Disease Progression After Single-Agent B-cell Maturation Antigen-Targeted Treatment in Multiple Myeloma: A Report of Three Cases in Sheikh Shakhbout Medical City"],"prefix":"10.7759","author":[{"given":"Waed","family":"Jaber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ammar","family":"Abdaljalil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Abu Haleeqa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayane","family":"Mheidly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0625","article-title":"Progress and paradigms in multiple myeloma","volume":"22","author":"Anderson KC","year":"2016","unstructured":"Anderson KC. Progress and paradigms in multiple myeloma. Clin Cancer Res. 2016, 22:5419-27. 10.1158\/1078-0432.CCR-16-0625","journal-title":"Clin Cancer Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau P","year":"2019","unstructured":"Moreau P, Attal M, Hulin C, et al.. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019, 394:29-38. 10.1016\/S0140-6736(19)31240-1","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi UH","year":"2019","unstructured":"Gandhi UH, Cornell RF, Lakshman A, et al.. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019, 33:2266-75. 10.1038\/s41375-019-0435-7","journal-title":"Leukemia"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S267404","article-title":"Belantamab mafodotin for the treatment of multiple myeloma: an overview of the clinical efficacy and safety","volume":"15","author":"Offidani M","year":"2021","unstructured":"Offidani M, Corvatta L, Mor\u00e8 S, Olivieri A. Belantamab mafodotin for the treatment of multiple myeloma: an overview of the clinical efficacy and safety. Drug Des Devel Ther. 2021, 15:2401-15. 10.2147\/DDDT.S267404","journal-title":"Drug Des Devel Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM- 2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial S","year":"2020","unstructured":"Lonial S, Lee HC, Badros A, et al.. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM- 2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020, 21:207-21. 10.1016\/S1470-2045(19)30788-0","journal-title":"Lancet Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129893","article-title":"Dreamm- 3: a phase 3, open-label, randomized study to evaluate the efficacy and safety of belantamab mafodotin (GSK2857916) monotherapy compared with pomalidomide plus low-dose dexamethasone (Pom\/Dex) in participants with relapsed\/refractory multiple myeloma (RRMM)","volume":"134","author":"Weisel K","year":"2019","unstructured":"Weisel K, Hopkins TG, Fecteau D, et al.. Dreamm- 3: a phase 3, open-label, randomized study to evaluate the efficacy and safety of belantamab mafodotin (GSK2857916) monotherapy compared with pomalidomide plus low-dose dexamethasone (Pom\/Dex) in participants with relapsed\/refractory multiple myeloma (RRMM). Blood. 2019, 134:1900. 10.1182\/blood-2019-129893","journal-title":"Blood"},{"key":"ref7","unstructured":"GSK Provides Update on DREAMM-3 Phase III Trial for Blenrep in Relapsed\/Refractory Multiple Myeloma. (2023). Accessed. January 20, 2023: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep\/."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos M","year":"2020","unstructured":"Dimopoulos M, Quach H, Mateos MV, et al.. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020, 396:186-97. 10.1016\/S0140-6736(20)30734-0","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-300970","article-title":"Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2","volume":"117","author":"Munshi NC","year":"2011","unstructured":"Munshi NC, Anderson KC, Bergsagel PL, et al.. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood. 2011, 117:4696-700. 10.1182\/blood-2010-10-300970","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00348-5","article-title":"Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response","volume":"10","author":"Abdallah N","year":"2020","unstructured":"Abdallah N, Rajkumar SV, Greipp P, et al.. Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. Blood Cancer J. 2020, 10:82. 10.1038\/s41408-020-00348-5","journal-title":"Blood Cancer J"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar SV","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, et al.. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014, 15:538-48. 10.1016\/S1470-2045(14)70442-5","journal-title":"Lancet Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-153443","article-title":"Belantamab mafodotin in patients with relapsed\/refractory multiple myeloma, a real-world experience","volume":"138","author":"Hultcrantz M","year":"2021","unstructured":"Hultcrantz M, Orozco J, Peterson TJ, et al.. Belantamab mafodotin in patients with relapsed\/refractory multiple myeloma, a real-world experience. Blood. 2021, 138:1644. 10.1182\/blood-2021-153443","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00592-3","article-title":"\"Real-life\" data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experience","volume":"11","author":"Vaxman I","year":"2021","unstructured":"Vaxman I, Abeykoon J, Dispenzieri A, et al.. \"Real-life\" data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experience. Blood Cancer J. 2021, 11:196. 10.1038\/s41408-021-00592-3","journal-title":"Blood Cancer J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-022-00212-5","article-title":"Real-world outcomes of belantamab mafodotin for relapsed\/refractory multiple myeloma (RRMM): preliminary results of a Spanish expanded access program (EAP)","volume":"11","author":"Alegre A","year":"2023","unstructured":"Alegre A, Benzo G, Alonso R, et al.. Real-world outcomes of belantamab mafodotin for relapsed\/refractory multiple myeloma (RRMM): preliminary results of a Spanish expanded access program (EAP). Oncol Ther. 2023, 11:83-96. 10.1007\/s40487-022-00212-5","journal-title":"Oncol Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065303","article-title":"The effect of belantamab mafodotin on primary myeloma-stroma co-cultures: asymmetrical mitochondrial transfer between myeloma cells and autologous bone marrow stromal cells","volume":"24","author":"Matula Z","year":"2023","unstructured":"Matula Z, Uher F, V\u00e1lyi-Nagy I, Mikala G. The effect of belantamab mafodotin on primary myeloma-stroma co-cultures: asymmetrical mitochondrial transfer between myeloma cells and autologous bone marrow stromal cells. Int J Mol Sci. 2023, 24:5303. 10.3390\/ijms24065303","journal-title":"Int J Mol Sci"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.266841","article-title":"BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice","volume":"108","author":"Zhou X","year":"2023","unstructured":"Zhou X, Rasche L, Kort\u00fcm KM, Mersi J, Einsele H. BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice. Haematologica. 2023, 108:958-68. 10.3324\/haematol.2020.266841","journal-title":"Haematologica"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-139181","article-title":"DREAMM- 7: a phase III study of the efficacy and safety of belantamab mafodotin (belamaf) with bortezomib, and dexamethasone (B-Vd) in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"136","author":"Rifkin RM","year":"2020","unstructured":"Rifkin RM, Boyd K, Grosicki S, et al.. DREAMM- 7: a phase III study of the efficacy and safety of belantamab mafodotin (belamaf) with bortezomib, and dexamethasone (B-Vd) in patients with relapsed\/refractory multiple myeloma (RRMM). Blood. 2020, 136:53-4. 10.1182\/blood-2020-139181","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8502","article-title":"safety and tolerability of belantamab mafodotin in combination with bortezomib\/dexamethasone in relapsed\/refractory multiple myeloma (RRMM)","volume":"38","author":"Nooka AK","year":"2020","unstructured":"Nooka AK, Stockerl-Goldstein K, Quach H. DREAMM- 6: safety and tolerability of belantamab mafodotin in combination with bortezomib\/dexamethasone in relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol. 2020, 38:8502. 10.1200\/JCO.2020.38.15_suppl.8502","journal-title":"J Clin Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-139785","article-title":"DREAMM- 8: a phase III study of the efficacy and safety of belantamab mafodotin with pomalidomide and dexamethasone (B-Pd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"136","author":"Trudel S","year":"2020","unstructured":"Trudel S, Davis R, Lewis NM, et al.. DREAMM- 8: a phase III study of the efficacy and safety of belantamab mafodotin with pomalidomide and dexamethasone (B-Pd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in patients with relapsed\/refractory multiple myeloma (RRMM). Blood. 2020, 136:4. 10.1182\/blood-2020-139785","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/165355-explosive-disease-progression-after-single-agent-b-cell-maturation-antigen-targeted-treatment-in-multiple-myeloma-a-report-of-three-cases-in-sheikh-shakhbout-medical-city","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:57:02Z","timestamp":1707508622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/165355-explosive-disease-progression-after-single-agent-b-cell-maturation-antigen-targeted-treatment-in-multiple-myeloma-a-report-of-three-cases-in-sheikh-shakhbout-medical-city"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,31]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.44433","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,31]]}}}